

DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS "HYGEIA SA"

SA Registration No. 13165/06/B/86/14

4 KIFISIAS AVENUE & ERYTHROU STAVROU STR., 15123 MAROUSI, ATHENS

Data and information for the period from January 1st 2008 to March 31st 2008

According to Decision No. 6/448/11.10.2007 by the BoD of the Hellenic Capital Market Commission



The following data and information aim at providing a general insight about the financial status and results of D.T.C.A. "Hygeia SA". Consequently, before proceeding to any investment decision or other transaction with the Company, we suggest the reader to visit the Company's web site, where the full annual financial statements are provided under the International Financial Reporting Standards, as well as the review report of the Certified Auditor-Accountant.

Site : www.hygeia.gr

Approval date of the interim financial statements by the Board of Directors May 8, 2008

BALANCE SHEET (Amounts in Euros)					INCOME STATEMENT (Amounts in Euros)																																																																																																																																	
	Group		Company			Group		Company																																																																																																																														
	31.3.2008	31.12.2007	31.3.2008	31.12.2007		01.01-31.03.2008	01.01-31.03.2007	01.01-31.03.2008	01.01-31.03.2007																																																																																																																													
ASSETS					Turnover																																																																																																																																	
Tangible Assets	198.748.325	173.339.584	101.098.686	100.773.071	66.119.087	27.774.468	33.206.196	27.997.502																																																																																																																														
Investments in property	171.241	171.883	171.241	171.883	Gross profit	16.215.845	7.265.213	7.933.869																																																																																																																														
Intangible assets	4.609.316	4.763.925	3.962.270	4.051.920	Earnings before taxes,																																																																																																																																	
Other non-current assets	284.141.598	280.303.587	306.451.178	293.875.825	from financing and investment results	12.838.353	5.961.427	6.201.762																																																																																																																														
Inventories	7.562.402	6.784.644	2.564.387	2.759.850	Profit / (loss) before taxes	8.383.088	6.354.036	2.407.042																																																																																																																														
Trade and other receivables	62.268.193	46.065.853	38.506.294	29.735.013	Profit / (loss) after taxes	5.855.121	5.623.708	1.627.871																																																																																																																														
Cash and cash equivalents	262.649.329	8.870.649	253.926.414	3.924.669	Allocated to:																																																																																																																																	
TOTAL ASSETS	820.150.403	520.300.126	706.680.471	435.292.231	Company shareholders	5.693.640	5.613.804	1.627.871																																																																																																																														
EQUITY & LIABILITIES					Minority interest	161.482	9.904																																																																																																																															
Share capital	51.508.673	51.508.673	51.508.673	51.508.673	Profit / (loss) after taxes per share –basic (in €)	0,05	0,13	0,01																																																																																																																														
Other equity items of Company shareholders	288.653.631	280.344.384	282.540.811	278.282.871	Earnings before taxes, from financing,																																																																																																																																	
Total net position of Company shareholders (a)	340.162.304	331.853.057	334.049.484	329.791.544	investment results and depreciations	15.809.381	7.533.928	7.878.702																																																																																																																														
Minority Interest (b)	10.681.424	5.304.207	0	0																																																																																																																																		
Total Net Position (c) = (b) + (a)	350.843.728	337.157.264	334.049.484	329.791.544	STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD																																																																																																																																	
Long-term Debt	326.959.829	22.233.845	297.653.682	0	(Amounts in Euros)																																																																																																																																	
Provisions & other Long-term liabilities	53.606.366	49.876.816	21.315.109	19.762.273	Group		Company																																																																																																																															
Short-term bank debt	30.750.207	64.680.912	20.095.775	55.327.998	31.3.2008	31.3.2007	31.3.2008	31.3.2007																																																																																																																														
Other short-term liabilities	57.990.272	46.351.289	33.566.421	30.410.416	Net worth in the beginning of the period(01.01.2008 and 01.01.2007 respectively)																																																																																																																																	
Total liabilities (d)	469.306.675	183.142.862	372.630.987	105.500.687	337.157.263	100.834.824	329.791.544	98.573.893																																																																																																																														
TOTAL EQUITY & LIABILITIES (c) + (d)	820.150.403	520.300.126	706.680.471	435.292.231	Earnings of period after taxes	5.855.121	5.613.804	1.627.871	6.016.399																																																																																																																													
CASH FLOW STATEMENT					Reserve for Balance Sheet conversion of foreign subsidiary companies	(14.461)	0	0	0																																																																																																																													
(Amounts in Euros)					Reserve of Convertible Bond Loan	2.630.070	0	2.630.070	0																																																																																																																													
Group		Company				Minority Interest from acquired Company	5.215.735	9.904	0																																																																																																																													
01.01-31.03.2008	01.01-31.03.2007	01.01-31.03.2008	01.01-31.03.2007	Total Net Worth of end period (31.03.2008 and 31.03.2007 respectively)																																																																																																																																		
Operating activities					350.843.727	106.458.532	334.049.484	104.590.292																																																																																																																														
Earnings before taxes	8.383.088	6.354.036	2.407.042	ADDITIONAL DATA & INFORMATION																																																																																																																																		
Plus / minus adjustments for:				1. The following companies are included in the consolidation:																																																																																																																																		
Depreciations	2.971.029	1.572.501	1.676.940	<table border="1"> <thead> <tr> <th>Company Name</th> <th>Corporate Seat</th> <th>Activity</th> <th>Participation percentage</th> <th>Consolidation method</th> <th>Participation relationship</th> <th>Tax unaudited financial years</th> </tr> </thead> <tbody> <tr> <td>HYGEIA SA</td> <td>Greece</td> <td>Health Services</td> <td>PARENT</td> <td></td> <td>PARENT</td> <td>2007</td> </tr> <tr> <td>Y-LOGIMED (former ALAN MEDICAL SA)</td> <td>Greece</td> <td>Imports - Trade and Procurement of medical-technological products</td> <td>100.00%</td> <td>Full</td> <td>Direct</td> <td>2006-2007</td> </tr> <tr> <td>MAGNETIC HYGEIA DIAGNOSTIC IMAGING SA</td> <td>Greece</td> <td>Health services</td> <td>20.00%</td> <td>Net worth</td> <td>Direct</td> <td>2007</td> </tr> <tr> <td>ANIZ SA</td> <td>Greece</td> <td>Operation of restaurant refreshment rooms</td> <td>70.00%</td> <td>Full</td> <td>Direct</td> <td>2007</td> </tr> <tr> <td>MITERA HOLDINGS SA</td> <td>Greece</td> <td>Participation in MITERA SA</td> <td>100.00%</td> <td>Full</td> <td>Direct</td> <td>2003-2007</td> </tr> <tr> <td>HYGEIA HOSPITAL – TIRANA SH.A</td> <td>Albania</td> <td>Health services</td> <td>80.00%</td> <td>Full</td> <td>Direct</td> <td>2007</td> </tr> <tr> <td>Y-PHARMA SA</td> <td>Greece</td> <td>Trade in pharmaceutical products and products of general medical use</td> <td>85.00%</td> <td>Full</td> <td>Direct</td> <td>2007</td> </tr> <tr> <td>STEM HEALTH SA</td> <td>Greece</td> <td>Stem Cell Medical Technology</td> <td>50.00%</td> <td>Full</td> <td>Direct</td> <td>2007</td> </tr> <tr> <td>STEM HEALTH HELLAS SA</td> <td>Greece</td> <td>Stem Cell Medical Technology</td> <td>74.28%</td> <td>Full</td> <td>Indirect</td> <td>—</td> </tr> <tr> <td>MITERA SA</td> <td>Greece</td> <td>Health services</td> <td>98.56%</td> <td>Full</td> <td>Direct and indirect</td> <td>2006-2007</td> </tr> <tr> <td>LETO SA</td> <td>Greece</td> <td>Health services</td> <td>69.11%</td> <td>Full</td> <td>Indirect</td> <td>2006-2007</td> </tr> <tr> <td>LETO HOLDINGS SA</td> <td>Greece</td> <td>Participation in LETO SA</td> <td>72.76%</td> <td>Full</td> <td>Indirect</td> <td>2003-2007</td> </tr> <tr> <td>ALPHA - LAB</td> <td>Greece</td> <td>Health services</td> <td>69.11%</td> <td>Full</td> <td>Indirect</td> <td>2003-2007</td> </tr> <tr> <td>VALLONE Co Ltd</td> <td>Cyprus</td> <td>Investments</td> <td>100.00%</td> <td>Full</td> <td>Direct</td> <td>1999-2007</td> </tr> <tr> <td>Chrysafalotissa Investments Ltd</td> <td>Cyprus</td> <td>Investments</td> <td>64.57%</td> <td>Full</td> <td>Indirect</td> <td>2002-2007</td> </tr> <tr> <td>Chrysafalotissa Public Ltd</td> <td>Cyprus</td> <td>Real Estate</td> <td>56.7%</td> <td>Full</td> <td>Indirect</td> <td>2002-2007</td> </tr> <tr> <td>Achilleion Ltd</td> <td>Cyprus</td> <td>Health services</td> <td>55.7%</td> <td>Full</td> <td>Indirect</td> <td>2002-2007</td> </tr> </tbody> </table>					Company Name	Corporate Seat	Activity	Participation percentage	Consolidation method	Participation relationship	Tax unaudited financial years	HYGEIA SA	Greece	Health Services	PARENT		PARENT	2007	Y-LOGIMED (former ALAN MEDICAL SA)	Greece	Imports - Trade and Procurement of medical-technological products	100.00%	Full	Direct	2006-2007	MAGNETIC HYGEIA DIAGNOSTIC IMAGING SA	Greece	Health services	20.00%	Net worth	Direct	2007	ANIZ SA	Greece	Operation of restaurant refreshment rooms	70.00%	Full	Direct	2007	MITERA HOLDINGS SA	Greece	Participation in MITERA SA	100.00%	Full	Direct	2003-2007	HYGEIA HOSPITAL – TIRANA SH.A	Albania	Health services	80.00%	Full	Direct	2007	Y-PHARMA SA	Greece	Trade in pharmaceutical products and products of general medical use	85.00%	Full	Direct	2007	STEM HEALTH SA	Greece	Stem Cell Medical Technology	50.00%	Full	Direct	2007	STEM HEALTH HELLAS SA	Greece	Stem Cell Medical Technology	74.28%	Full	Indirect	—	MITERA SA	Greece	Health services	98.56%	Full	Direct and indirect	2006-2007	LETO SA	Greece	Health services	69.11%	Full	Indirect	2006-2007	LETO HOLDINGS SA	Greece	Participation in LETO SA	72.76%	Full	Indirect	2003-2007	ALPHA - LAB	Greece	Health services	69.11%	Full	Indirect	2003-2007	VALLONE Co Ltd	Cyprus	Investments	100.00%	Full	Direct	1999-2007	Chrysafalotissa Investments Ltd	Cyprus	Investments	64.57%	Full	Indirect	2002-2007	Chrysafalotissa Public Ltd	Cyprus	Real Estate	56.7%	Full	Indirect	2002-2007	Achilleion Ltd	Cyprus	Health services	55.7%	Full	Indirect	2002-2007
Company Name	Corporate Seat	Activity	Participation percentage	Consolidation method	Participation relationship	Tax unaudited financial years																																																																																																																																
HYGEIA SA	Greece	Health Services	PARENT		PARENT	2007																																																																																																																																
Y-LOGIMED (former ALAN MEDICAL SA)	Greece	Imports - Trade and Procurement of medical-technological products	100.00%	Full	Direct	2006-2007																																																																																																																																
MAGNETIC HYGEIA DIAGNOSTIC IMAGING SA	Greece	Health services	20.00%	Net worth	Direct	2007																																																																																																																																
ANIZ SA	Greece	Operation of restaurant refreshment rooms	70.00%	Full	Direct	2007																																																																																																																																
MITERA HOLDINGS SA	Greece	Participation in MITERA SA	100.00%	Full	Direct	2003-2007																																																																																																																																
HYGEIA HOSPITAL – TIRANA SH.A	Albania	Health services	80.00%	Full	Direct	2007																																																																																																																																
Y-PHARMA SA	Greece	Trade in pharmaceutical products and products of general medical use	85.00%	Full	Direct	2007																																																																																																																																
STEM HEALTH SA	Greece	Stem Cell Medical Technology	50.00%	Full	Direct	2007																																																																																																																																
STEM HEALTH HELLAS SA	Greece	Stem Cell Medical Technology	74.28%	Full	Indirect	—																																																																																																																																
MITERA SA	Greece	Health services	98.56%	Full	Direct and indirect	2006-2007																																																																																																																																
LETO SA	Greece	Health services	69.11%	Full	Indirect	2006-2007																																																																																																																																
LETO HOLDINGS SA	Greece	Participation in LETO SA	72.76%	Full	Indirect	2003-2007																																																																																																																																
ALPHA - LAB	Greece	Health services	69.11%	Full	Indirect	2003-2007																																																																																																																																
VALLONE Co Ltd	Cyprus	Investments	100.00%	Full	Direct	1999-2007																																																																																																																																
Chrysafalotissa Investments Ltd	Cyprus	Investments	64.57%	Full	Indirect	2002-2007																																																																																																																																
Chrysafalotissa Public Ltd	Cyprus	Real Estate	56.7%	Full	Indirect	2002-2007																																																																																																																																
Achilleion Ltd	Cyprus	Health services	55.7%	Full	Indirect	2002-2007																																																																																																																																
Provisions	568.902	378.789	131.110	A) The consolidated financial statements include for the first time the following companies:																																																																																																																																		
Income from use of provisions for previous periods	0	(1.840.901)	0	a) Group Valone Co Ltd that controls direct & indirect through the company "Chrysafalotissa Investment Ltd" the 56.7% stake of the company "Chrysafalotissa Public Ltd" in Cyprys Limassol that controls directly 100% of the company "Medical Center Limassol Achillion Ltd" since it assumed the control from 18.01.2008 and b) the company «STEM HEALTH HELLAS S.A.» that is direct holding by 50% stake of the subsidiary company "MITERA S.A." and by 50% stake of the subsidiary company "STEM HEALTH SA".																																																																																																																																		
Results (Income, expenses, earnings and losses) from investment activities	(1.916.015)	(20.616)	(1.829.137)	B) Moreover, the consolidated financial statements (a) with the method of Full Consolidation the group MITERA S.A., while for the corresponding period it had been consolidated with the Y Method. The group MITERA was Full Consolidated for the first time in the financial statements of 31.12.2007. and b) the company "Hygeia Hospital Tirana SH.A", "Y-Pharma S.A." and "Stem Health S.A." that were included for the first time on the consolidated financial statements of HYGEIA Group on 30.06.2007 and were not included the same period last year.																																																																																																																																		
Depreciations of subsidies	(8.729)	0	0	2. On 10.1.2008, concluded the issue of the company's Convertible Bond Loan amount of EUR 300,015,000 with the issue of 66,670,000 bonds, of nominal value EUR 4.50 each. The duration is 5-years and the interest rate of the first payment period., that begins on January 10,2008 and expires on April 10, 2008 amounts to 5.598% annually.																																																																																																																																		
Profit / (Loss) from associate companies	(43.693)	(1.116.429)	0	3. The company has made a cumulative provision of EUR 1.1 million for legal cases. The amount of equivalent provision for the group is circa EUR 7.2 million. Substantial surcharges from other litigious or under arbitration disputes and decisions of judicial instruments exceeding the provision already made are not expected to arise.																																																																																																																																		
Financial Expenses	6.414.943	744.436	5.623.858	4. The company made a cumulative provision of EUR 375 thousands for unaudited fiscal years. The amount of equivalent provision for the group is circa EUR 755 thousands.																																																																																																																																		
Plus / minus adjustments for changes in working capital accounts or changes related to operating activities:				5. On 31.03.2008, the Group's staff amounted to 2,294 individuals (31.03.2007 : 1,066) and the company's staff amounted to 1,069 (31.03.2007 : 1,024)																																																																																																																																		
Decrease / (increase) in other Long-term receivables	(2.765.251)	(38.029)	(2.678.634)	6. The cumulative amounts of the company's and the group's purchases/sales (including the income from dividends) from and to affiliated parties from the beginning of the budgetary year, as well as the balances of the company's and the group's liabilities/ receivables with the affiliated parties at the end of the current year are presented in the following table:																																																																																																																																		
Decrease / (increase) in inventories	117.418	(122.611)	195.462	<table border="1"> <thead> <tr> <th></th> <th>Group</th> <th>Company</th> </tr> </thead> <tbody> <tr> <td>a) Sales of products and services</td> <td>101,213</td> <td>184,042</td> </tr> <tr> <td>b) Purchases of products and services</td> <td>89,502</td> <td>4,220,752</td> </tr> <tr> <td>c) Receivables</td> <td>311,314</td> <td>354,8</td> </tr> <tr> <td>d) Liabilities</td> <td>198,707</td> <td>4,464,065</td> </tr> <tr> <td>e) Transactions and payments of senior executives and administration members</td> <td>892,832</td> <td>550,703</td> </tr> <tr> <td>f) Receivables from senior executives and administration members</td> <td>0</td> <td>0</td> </tr> <tr> <td>g) Liabilities towards senior executives and administration members</td> <td>24,505</td> <td>0</td> </tr> </tbody> </table>						Group	Company	a) Sales of products and services	101,213	184,042	b) Purchases of products and services	89,502	4,220,752	c) Receivables	311,314	354,8	d) Liabilities	198,707	4,464,065	e) Transactions and payments of senior executives and administration members	892,832	550,703	f) Receivables from senior executives and administration members	0	0	g) Liabilities towards senior executives and administration members	24,505	0																																																																																																						
	Group	Company																																																																																																																																				
a) Sales of products and services	101,213	184,042																																																																																																																																				
b) Purchases of products and services	89,502	4,220,752																																																																																																																																				
c) Receivables	311,314	354,8																																																																																																																																				
d) Liabilities	198,707	4,464,065																																																																																																																																				
e) Transactions and payments of senior executives and administration members	892,832	550,703																																																																																																																																				
f) Receivables from senior executives and administration members	0	0																																																																																																																																				
g) Liabilities towards senior executives and administration members	24,505	0																																																																																																																																				
Decrease / (increase) in receivables	(13.920.900)	(2.880.032)	(7.045.852)	7. The Parent's and the Group's Financial Statements of 31.03.2008 were approved by the company's Board of Directors on 08.05.2008.																																																																																																																																		
(Decrease) / Increase in liabilities (minus banks liabilities)	4.502.959	2.895.649	(510.870)	8. No encumbrances on the company's fixed assets exist.																																																																																																																																		
Decrease / (Increase) of Provisions	0	226.657	0	9. The earnings per share have been estimated based on the weighted average number of shares.																																																																																																																																		
Minus:																																																																																																																																						
Interests payable and relevant expenses paid	(1.317.338)	(801.581)	(832.092)																																																																																																																																			
Total inflow / (outflow) from operating activities (a)	2.986.412	5.351.868	(2.862.173)																																																																																																																																			
Investment activities																																																																																																																																						
Acquisition of subsidiaries, associates, ventures and other investments	(6.587.983)	(1.471.738)	(9.912.585)																																																																																																																																			
Purchase of tangible and intangible fixed assets	(3.652.556)	(453.197)	(1.912.263)																																																																																																																																			
Revenues from the sale of tangible and intangible fixed assets	(58.691)	0	0																																																																																																																																			
Interests Received	90.586	20.616	3.708																																																																																																																																			
Total inflow / (outflow) from investment activities (b)	(10.208.644)	(1.904.319)	(11.821.140)																																																																																																																																			
Financing activities																																																																																																																																						
Net inflows /(outflows) of loans	311.029.794	0	306.974.386																																																																																																																																			
Payments of loans	(49.703.409)	0	(42.252.481)																																																																																																																																			
Payments of liabilities from financing leases (sinking funds)	(325.474)	(88.295)	(36.847)																																																																																																																																			
Total inflow / (outflow) from financing activities (c)	261.000.911	(88.295)	264.685.059																																																																																																																																			
Total increase / (decrease) in cash flow and cash equivalents of the period (a) + (b) + (c)	253.778.679	3.359.254	250.001.746																																																																																																																																			
Cash and cash equivalents in the beginning of the period	8.870.649	5.294.501	3.924.669																																																																																																																																			
Cash and cash equivalents at the end of the period	262.649.329	8.653.756	253.926.414																																																																																																																																			

THE BoD CHAIRMAN	THE CHIEF EXECUTIVE OFFICER	Maroussi, May, 13 2008 GROUP CEO	THE DEPUTY FINANCE DIRECTOR	THE HEAD ACCOUNTANT
KON. STAVROU ID No. A 049114	PASCH. BOUCHORIS ID No. AA019554	DAVID ARAR ID No. Σ264433	EL. KELEPOURI ID No. Σ 028050	G. NOMIKOS ID No.Σ 014543